Resilience
Resilience, formally known as National Resilience, Inc., is a biopharmaceutical manufacturing and technology company based in La Jolla, California. Established in 2020, Resilience focuses on enhancing the accessibility of complex medicines while safeguarding biopharmaceutical supply chains. The company specializes in providing comprehensive manufacturing and development solutions across a range of therapeutic modalities, including cell and gene therapies, viral vectors, vaccines, and proteins. With a commitment to developing innovative manufacturing technologies, Resilience offers customized and scalable processes tailored to the varying needs of its clients throughout the drug development lifecycle, from pre-clinical stages to commercial supply. The company's facilities are designed to meet high-quality standards and regulatory requirements for the production of complex and novel medicines.
Cellevolve Bio is a development and commercialization company specializing in cell therapies aimed at neglected diseases. The company collaborates with innovators to transition early-stage clinical therapies into commercially available treatments, particularly for pediatric and rare diseases. By advancing these therapies into clinical development, Cellevolve aims to significantly enhance patient outcomes and provide expertise in cell therapy and clinical care.
Elpis Biomed aims to become a leading, global supplier of in vitro cell types for academic research and commercial drug discovery & development purposes. The cells could provide an alternative to the limited supply of primary cells and replace animal studies in other cases. Elpis Biomed’s proprietary technology allows rapid generation of highly mature, differentiated cell types at unmatched purity. The process is scalable with the potential to expand product offering with additional cell-types in the neuro-mesoderm focus area. Initial products will be cortical neurons, oligodendrocytes and skeletal muscle cells to be sold to academic research groups and pharma/biotech customers.
Garuda Therapeutics is a biotechnology company focused on creating off-the-shelf hematopoietic stem cell therapies aimed at treating various severe and life-threatening conditions. The company specializes in addressing blood, bone marrow, immune, and metabolic diseases. By leveraging expertise in innovative research methods, including the use of zebrafish, mice, and human-induced pluripotent stem cells, Garuda analyzes novel genes and mechanisms vital for blood formation. This approach enables the development of mechanism-based therapies designed to improve patient outcomes.
The company was founded in 1999 as a company focused on R&D for biopharmaceuticals and medical devices (Nanotherapeutics). In 2017 the company was transformed (and renamed) as a biologics CDMO providing manufacturing up to BSL-3.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at
support@teaserclub.com. Your feedback is most welcome.